Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.

Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients’ quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study’s key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.